Patient Case Introduction: 66-year-old Male Diagnosed with R/R MM
Subject matter experts share strategies for determining treatment selection and duration for patients with transplant-ineligible NDMM.
Clinical Insights Concerning the Management of Patients with NDMM
New Trial Data Informing Optimal Care of Frail Patients with NDMM
Ajay Nooka, MD, MPH, FACP leads a survey of the MAIA study, including a sub-group analysis of the MAIA study in frail patients, as well as findings from the MagnetisMM-6 study.
Patient Case Introduction: A 76-year-old Female Diagnosed with Transplant-ineligible NDMM
Jonathan Kaufman, MD describes a second patient case featuring a 76-year-old female diagnosed with transplant-ineligible NDMM.
NDMM Risk-Stratification and Other Factors Informing Treatment Selection
Defining transplant eligibility, explaining the role of transplant in NDMM, and differentiating between high- and low-risk MM.
Key Trial Data Guiding Treatment Decisions for Patients with NDMM
Thoughtful discussion centered around recently presented updates to the GRIFFIN, MASTER, and GMMG-CONCEPT studies in NDMM patients.
An Introduction to Treatment Strategies for Patients with NDMM
Nisha Joseph, MD leads an introduction to induction regimen options for patients with transplant-eligible NDMM.
Patient Case Introduction: A 65-year-old Female Diagnosed with Transplant-eligible NDMM
Moderator Sagar Lonial, MD, FACP, and colleagues engage with the first patient case: a 65-year-old female diagnosed with transplant-eligible NDMM.
Unmet Needs and the Future of Multiple Myeloma
Experts muse on the unmet needs of multiple myeloma, and exciting investigational therapies on the horizon.
Novel Therapies in Multiple Myeloma
A look at the role of bispecifics and CAR T-cell therapies in the multiple myeloma treatment landscape.
Case Presentation: A 74-Year-Old Woman with Relapsed/Refractory Multiple Myeloma
Experts discuss the case of a woman with relapsed/refractory multiple myeloma and the available treatment options, including novel BCMA-targeted agents.
Blood-Based MRD Testing and Transplant-Ineligible Multiple Myeloma
Key opinion leaders describe the role of blood-based MRD testing in the transplant-ineligible multiple myeloma treatment landscape.
Transplant-Ineligible Multiple Myeloma: The SWOG0777 Study
Nisha Joseph, MD, presents the case of a 78-year-old man with transplant-ineligible multiple myeloma and discusses treatment strategy.
Defining High-Risk Multiple Myeloma
Experts discuss how they define frail and high-risk patients with multiple myeloma and their treatment approaches for these patient populations.
Transplant-Ineligible Multiple Myeloma: The MAIA Trial
An overview of the study design, efficacy, and safety findings of the MAIA trial.
Case Presentation: An 82-Year-Old Woman with Transplant-Ineligible Multiple Myeloma
Dr Nisha Joseph presents the case of a woman with transplant-ineligible multiple myeloma and discusses considerations when choosing frontline treatment regimens.
Maintenance Therapy Strategies for Transplant Eligible Multiple Myeloma
Drs Ajay Nooka and Jonathan Kaufman discuss maintenance and consolidation treatment strategies for transplant eligible multiple myeloma.
Treatment Approaches for Patients with Newly Diagnosed Multiple Myeloma
Experts discuss how they select a treatment regimen for a newly diagnosed multiple myeloma patient, and how they measure a successful treatment response.
Newly Diagnosed Multiple Myeloma: The MASTER and GMMG-HD7 Trials
A review of the study design and results of two clinical trials researching quadruplet therapies for newly diagnosed multiple myeloma presented at ASH 2021.
Emory Experts Discuss Multi-Agent Induction Regimens for Transplant-Eligible Newly Diagnosed Myeloma
An overview of the currently available frontline treatment options for transplant-eligible multiple myeloma.
2 Clarke Drive Cranbury, NJ 08512